IGF1R and Ewing sarcoma: Combined inhibition of IGF-IR and mTOR by cixutumumab, a humanized anti-IGF-IR-IgG1 monoclonal antibody and temsirolimus led to a >20% tumor volume reduction in two of three ES patients.